References

1. Kuip E1, Muller E. Fatal pneumonitis after treatment with docetaxel and trastuzumab. Neth J Med. 2009 ;67(6):237-9. PubMed | Google Scholar


2. Kunitoh H, Watanabe K, Onoshi T, Furuse K, Niitani H, Taguchi T. Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer: a Japanese cooperative study. J Clin Oncol. 1996 ;14(5):1649-55. PubMed | Google Scholar


3. Valero V, Holmes FA, Walters RS et al. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol. 1995 ;13(12):2886-94. PubMed | Google Scholar


4. Ravdin PM, Burris HA, Cook G et al. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol. 1995; 13(12):2879-85. PubMed | Google Scholar


5. Nagata S, Ueda N, Yoshida Y, Matsuda H, Maehara Y . Severe interstitial pneumonitis associated with the administration of taxanes. J Infect Chemother. 2010; 16(5):340-4. PubMed | Google Scholar


6. Mileshkin L, Prince H, Rischin D, Zimet A. Severe interstitial pneumonitis following high-dose cyclophosphamide, thiotepa and docetaxel: two case reports and a review of the literature. Bone Marrow Transplant. 2001 ;27(5):559-63. PubMed | Google Scholar


7. Wong P, Leung AN, Berry GJ, Atkins KA, Montoya JG, Ruoss SJ et al. Paclitaxel-induced hypersensitivity pneumonitis:radiographic and CT findings. Am J Roentgenol. 2001; 176(3):718-20. PubMed | Google Scholar


8. Read WL, Mortimer JE, Picus J. Severe interstitial pneumonitis associated with docetaxel administration. Cancer. 2002; 94(3):847-53. PubMed | Google Scholar